These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 22024030)

  • 1. Structure-based design of isoindoline-1,3-diones and 2,3-dihydrophthalazine-1,4-diones as novel B-Raf inhibitors.
    Wang X; Salaski EJ; Berger DM; Powell D; Hu Y; Wojciechowicz D; Collins K; Frommer E
    Bioorg Med Chem Lett; 2011 Dec; 21(23):6941-4. PubMed ID: 22024030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel BRAF kinase inhibitors with structure-based virtual screening.
    Park H; Choi H; Hong S; Hong S
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5753-6. PubMed ID: 21873050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-oxime pyrazole based inhibitors of B-Raf kinase.
    Newhouse BJ; Hansen JD; Grina J; Welch M; Topalov G; Littman N; Callejo M; Martinson M; Galbraith S; Laird ER; Brandhuber BJ; Vigers G; Morales T; Woessner R; Randolph N; Lyssikatos J; Olivero A
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3488-92. PubMed ID: 21536432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.
    Ren L; Laird ER; Buckmelter AJ; Dinkel V; Gloor SL; Grina J; Newhouse B; Rasor K; Hastings G; Gradl SN; Rudolph J
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1165-8. PubMed ID: 22196124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-Raf kinase inhibitors for cancer treatment.
    Li N; Batt D; Warmuth M
    Curr Opin Investig Drugs; 2007 Jun; 8(6):452-6. PubMed ID: 17621874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IRAK-4 inhibitors. Part II: a structure-based assessment of imidazo[1,2-a]pyridine binding.
    Buckley GM; Ceska TA; Fraser JL; Gowers L; Groom CR; Higueruelo AP; Jenkins K; Mack SR; Morgan T; Parry DM; Pitt WR; Rausch O; Richard MD; Sabin V
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3291-5. PubMed ID: 18482836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity.
    Lyne PD; Aquila B; Cook DJ; Dakin LA; Ezhuthachan J; Ioannidis S; Pontz T; Su M; Ye Q; Zheng X; Block MH; Cowen S; Deegan TL; Lee JW; Scott DA; Custeau D; Drew L; Poondru S; Shen M; Wu A
    Bioorg Med Chem Lett; 2009 Feb; 19(3):1026-9. PubMed ID: 19097792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hit to lead optimization of pyrazolo[1,5-a]pyrimidines as B-Raf kinase inhibitors.
    Gopalsamy A; Ciszewski G; Shi M; Berger D; Hu Y; Lee F; Feldberg L; Frommer E; Kim S; Collins K; Wojciechowicz D; Mallon R
    Bioorg Med Chem Lett; 2009 Dec; 19(24):6890-2. PubMed ID: 19884006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The identification of potent, selective and CNS penetrant furan-based inhibitors of B-Raf kinase.
    Takle AK; Bamford MJ; Davies S; Davis RP; Dean DK; Gaiba A; Irving EA; King FD; Naylor A; Parr CA; Ray AM; Reith AD; Smith BB; Staton PC; Steadman JG; Stean TO; Wilson DM
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4373-6. PubMed ID: 18621524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.
    Wenglowsky S; Moreno D; Laird ER; Gloor SL; Ren L; Risom T; Rudolph J; Sturgis HL; Voegtli WC
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6237-41. PubMed ID: 22954737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors.
    Ramurthy S; Aikawa M; Amiri P; Costales A; Hashash A; Jansen JM; Lin S; Ma S; Renhowe PA; Shafer CM; Subramanian S; Sung L; Verhagen J
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3286-9. PubMed ID: 21543226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?
    Van Goethem S; Matheeussen V; Joossens J; Lambeir AM; Chen X; De Meester I; Haemers A; Augustyns K; Van der Veken P
    J Med Chem; 2011 Aug; 54(16):5737-46. PubMed ID: 21711053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knowledge-based design of 7-azaindoles as selective B-Raf inhibitors.
    Tang J; Hamajima T; Nakano M; Sato H; Dickerson SH; Lackey KE
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4610-4. PubMed ID: 18662874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The identification of potent and selective imidazole-based inhibitors of B-Raf kinase.
    Takle AK; Brown MJ; Davies S; Dean DK; Francis G; Gaiba A; Hird AW; King FD; Lovell PJ; Naylor A; Reith AD; Steadman JG; Wilson DM
    Bioorg Med Chem Lett; 2006 Jan; 16(2):378-81. PubMed ID: 16260133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors.
    Dietrich J; Gokhale V; Wang X; Hurley LH; Flynn GA
    Bioorg Med Chem; 2010 Jan; 18(1):292-304. PubMed ID: 19962319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-Raf kinase inhibitors: hit enrichment through scaffold hopping.
    Gopalsamy A; Shi M; Hu Y; Lee F; Feldberg L; Frommer E; Kim S; Collins K; Wojciechowicz D; Mallon R
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2431-4. PubMed ID: 20307980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation.
    Jaramillo C; de Diego JE; Hamdouchi C; Collins E; Keyser H; Sánchez-Martínez C; del Prado M; Norman B; Brooks HB; Watkins SA; Spencer CD; Dempsey JA; Anderson BD; Campbell RM; Leggett T; Patel B; Schultz RM; Espinosa J; Vieth M; Zhang F; Timm DE
    Bioorg Med Chem Lett; 2004 Dec; 14(24):6095-9. PubMed ID: 15546737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships.
    Wenglowsky S; Ahrendt KA; Buckmelter AJ; Feng B; Gloor SL; Gradl S; Grina J; Hansen JD; Laird ER; Lunghofer P; Mathieu S; Moreno D; Newhouse B; Ren L; Risom T; Rudolph J; Seo J; Sturgis HL; Voegtli WC; Wen Z
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5533-7. PubMed ID: 21802293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors.
    Ramurthy S; Costales A; Jansen JM; Levine B; Renhowe PA; Shafer CM; Subramanian S
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1678-81. PubMed ID: 22264479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase.
    Cockcroft XL; Dillon KJ; Dixon L; Drzewiecki J; Kerrigan F; Loh VM; Martin NM; Menear KA; Smith GC
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1040-4. PubMed ID: 16290932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.